Kidney Disease Clinical Trialists 8th Edition 2024
$70.00
This Product is shared via google drive download link, So please share your correct Gmail id while placing the order .Please note that there are no CME points or certificate associated with this course Samples for Courses Can be found here : Free Samples Here!
+ Include: 9 videos, size: 17.5 GB
Kidney Disease Clinical Trialists 8th Edition 2024
+ Include: 9 videos, size: 17.5 GB
Kidney Disease Clinical Trialists 8th Edition 2024
+ Information:
The Kidney Disease Clinical Trialists (KDCT) 8th Edition 2024 Workshop will be held on March 15-16, 2024, in Washington DC. This high-level think tank event will feature an exceptional expert faculty and a limited number of attendees, including distinguished nephrologists, clinical trialists, principal investigators, and statisticians from academia, R&D pharma and device companies, NIH, EMA, PMDA, FDA, and payers.
The workshop aims to foster an international exchange of ideas on trial design, conduct, ethics, interpretation, approvability, and implementation encompassing drugs, devices, biomarkers, and therapeutic strategies for kidney disease
The Kidney Disease Clinical Trialists (KDCT) 8th Edition 2024 Workshop is designed for a select group of professionals involved in kidney disease research and clinical trials. The target audience includes:
- Nephrologists
- Clinical trialists
- Principal investigators
- Statisticians
- Researchers from academia
- Professionals from R&D pharma and device companies
- Representatives from regulatory bodies like NIH, EMA, PMDA, and FDA
- Payers
- Patient advocates
This workshop aims to foster an international exchange of ideas on trial design, conduct, ethics, interpretation, approvability, and implementation of therapeutic strategies for kidney disease.
+ Topics:
- SESSION 1 EGFR SLOPE VS EGFR DELTA AS AN ENDPOINT PROS AND CONS.mp4
- SESSION 2 COMBINATION THERAPY IN CKD.mp4
- SESSION 3 Focus on IGAN.mp4
- SESSION 4 Shifting earlg deveIOpment trials from the EGFR UACR ratio paradigm to a multiplexed biomarker enabled strategy.mp4
- SESSION 5 Are simplified consents desirable achievable.mp4
- SESSION 6 Dialysis and Vascular Access.mp4
- SESSION 7 How to assess the renal benefit of weight loss drugs (i.e.drugs that can affect lean bodg mass).mp4
- SESSION 8 Endpoints in AKI trials to guide generation of Core Outcome data Set.mp4
- SESSION 9 Developing Core Outcomes Sets in AKI trials.mp4
Related products
Anesthesiology & pain medicine
Anesthesiology & pain medicine
Courses